Physician profile
Amy E Wall
NPI 1346751195
$5,577.19
in general payments reported to CMS, 2019-2025
28 companies · $982 in 2025
The $982 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $920 · 2022: $1,110 · 2023: $1,344 · 2024: $1,221 · 2025: $982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,547.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,051.90 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $966.07 | 2021-2025 | Farxiga, Lokelma, Wainua |
| Novartis Pharmaceuticals Corporation | $895.88 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $565.52 | 2022-2025 | Verquvo, Keytruda, Capvaxive |
| Pfizer INC. | $443.26 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $193.61 | 2021-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $151.28 | 2022-2025 | Amvuttra, Onpattro |
| E.R. Squibb & Sons, L.L.C. | $139.54 | 2022-2023 | Camzyos, Eliquis |
| Boston Scientific Corporation | $121.64 | 2023 | Watchman |
| Amgen INC. | $108.41 | 2022-2023 | Repatha |
| Lexicon Pharmaceuticals, INC. | $103.41 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $96.46 | 2021-2025 | |
| Cvrx, INC. | $93.76 | 2023-2025 | Barostim Neo System |
| Inspire Medical Systems, INC. | $83.74 | 2025 | Inspire |
| Scpharmaceuticals INC. | $81.48 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $80.83 | 2023 | Optimizer |
| Abbott Laboratories | $75.63 | 2023-2024 | Gallant |
| Medtronic, INC. | $65.15 | 2022-2025 | Cobalt Dr Mri Surescan |
| Philips North America LLC | $36.05 | 2025 | Lm Undivided |
| Heartflow, INC. | $34.88 | 2022 | |
| Bridgebio Pharma, INC. | $32.94 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $32.47 | 2024 | Arcalyst |
| Novo Nordisk INC | $28.36 | 2023 | Ozempic, Rybelsus |
| United Therapeutics Corporation | $24.87 | 2024 | Tyvaso |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.63 | 2021-2022 | |
| Esperion Therapeutics, INC. | $19.33 | 2021 | |
| Daiichi Sankyo INC. | $17.02 | 2023 | Injectafer |
| Kiniksa Pharmaceuticals, Ltd. | $14.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.